The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.” ...

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...

The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...

In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was "taking these difficult but necessary actions” as it focuses on “the long-term success of our core ...

The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...

investigators and study staff for their participation in our clinical trials,” co-founder and CEO Anne Wojcicki said in a ...

As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.

The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...